Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

110.49
+1.311.20%
Post-market: 110.24-0.2500-0.23%19:35 EDT
Volume:273.50K
Turnover:30.13M
Market Cap:1.03B
PE:89.53
High:110.70
Open:109.16
Low:108.66
Close:109.18
52wk High:118.00
52wk Low:90.60
Shares:9.34M
Float Shares:9.34M
Volume Ratio:0.90
T/O Rate:2.93%
Dividend:2.14
Dividend Rate:1.94%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):142.30

Loading ...

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
5 hours ago

U.S. Stocks on the MOVE -VF Corp, Biogen, AbbVie

Reuters
·
8 hours ago

Sector Update: Healthcare

MT Newswires Live
·
8 hours ago

Novo Nordisk price target lowered to DKK 296 from DKK 310 at Citi

TIPRANKS
·
9 hours ago

Novartis AG Rises Friday, Outperforms Market

Dow Jones
·
9 hours ago

Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand

MT Newswires Live
·
9 hours ago

Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market

Dow Jones
·
9 hours ago

UBS Lifts AbbVie Target as Focus Expands Beyond Immunology Drugs

Reuters
·
Yesterday

1 Drugs Could Ease Back and Knee Pain, but Doctors Say There are Risks for Older Adults

Dow Jones
·
Yesterday

BofA Securities Adjusts Eli Lilly Price Target to $1,341 From $1,344, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Abbvie Inc. : UBS Raises Target Price to $275 from $260

THOMSON REUTERS
·
Yesterday

Merck & Company (MRK) Receives a Buy from UBS

TIPRANKS
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Yesterday

Merck price target lowered to $163 from $166 at BofA

TIPRANKS
·
Yesterday

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
Yesterday

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
Yesterday

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
Yesterday

Eli Lilly: Improvements were Maintained or Further Improved Through Week 52, with Safety Consistent with Known Profile of Each Respective Medicine

THOMSON REUTERS
·
Yesterday

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Advance Understanding of the Interconnected Immune and Metabolic Biology in Adults with Psoriasis and Obesity

THOMSON REUTERS
·
Yesterday